Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy

As reported by Business News

The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Business News ↗

Market Samachar is a news aggregator. This article was originally published by Business News. Tap the button above to read the full story on their site.

INDIAN CVC-backed Bamboo Insurance targets $3.24 billion valuation in US IPO Markets-Economic Times
INDIAN Copper price hits three-week low as inventories rise and dollar strengthens Markets-Economic Times
INDIAN US Senate Republicans release new crypto bill text ahead of critical vote Markets-Economic Times
INDIAN Crypto data firm Kaiko secures $110 million funding round led by S&P Global Markets-Economic Times
INDIAN Gold, silver prices retreat as oil prices surge, inflation and rate-hike concerns mount Markets-Economic Times
INDIAN Bond market shock: 10-year US Treasury yield tops 5% as oil spike puts Federal Reserve on rate-hike path Markets-Economic Times
INDIAN US stocks today: US stocks slip as AI slowdown fears drag Nvidia and chipmakers Markets-Economic Times
INDIAN BHEL approves ₹65 crore further investment in NTPC joint venture NBPPL mint - markets

Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy

More from Market Samachar